India’s drug regulator has sharply tightened its pharmacovigilance rules, requiring companies to report serious adverse drug effects within 15 days and other reactions within 90 days. Effective 1 February, the new DCGI guidance aims to strengthen oversight of the country’s pharmaceutical industry.